Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- EGY +32.6%, CVU +31.6%, XXII +31.3%, VRX +14.3%, REPH +14.1%, BSM +11.2%, CAMT +11.2%, NVMI +10.2%, ODP +9.6%, FN +9.2%, ARLZ +9.1%,DQ +7.1%, CYD +6.8%, SBRA +6.6%, CHEK +6.6%, GNRT +6.6%, TDOC +6.1%, QTNA +5.7%, AEZS +5.6%, WRLD +5.5%, RGR +5.4%, (also announces expansion of its stock repurchase program to $100 million ),MAR +5.3%, ENDP +5.1%, NVAX +4.9%, BLDR +4.8%, EGLE +4.5%, ZBRA +4.5%, TCMD +4.3%, P +4.3%, (also KKR invests $150 mln in convertible preferred stock, get Board seat; Board also forming independent committee to look for new Directors), GPOR +4.2%, USAT +4%, SXE +3.9%,HSIC +3.5%, SSH +3.4%, DLA +3.2%, SAND +3%, SAND +3%, BKD +2.8%,XRAY +2.8%, GLP +2.4%, IONS +2.2%, NEOS +2.2%, STWD +1.9%, CBOE +1.9%, ACRX +1.8%, OAS +1.6%, (also announces plans for an initial public offering of certain of its midstream assets), AGN +1.3%, PRTY +1.3%, NXST +1.2%, AXSM +1.1%, LGIH +1.1%, RBC +1%, FHCO +1%
M&A news:
- DPLO +2.8% ( completes acquisition of WRB Communications for $24.5 million cash and $4.5 million of Diplomat common stock)
Other news:
- CLNT +40.7% (YSK 1860 disclosed 29.4% active stake pursuant to Share Purchase Agreement )
- SNGX +13.3% (granted a Japanese patent for ThermoVax,including coverage of its ricin toxin vaccine candidate, RiVax)
- ROKA +13.2% (enters 5-year non-exclusive distribution agreement with FoodChek Systems Inc. to distribute their lines of both proprietary Actero ELITE Enrichment Media and non-proprietary Actero UNIVERSAL Enrichment Media)
- REPH +12.6% (announces 'successful' top-line results from its Phase III safety study evaluating intravenous meloxicam)
- ORIG +10.3% (announces the deadline for holders of term loans of Drillships Financing Holding and Drillships Ocean Ventures has been extended)
- DHXM +6% (continued strength following Sohn mention)
- BTX +5.5% (presents new data from the Phase I/IIa clinical trial of OpRegen in the advanced form of dry age-related macular degeneration)
- RAD +4% (Rite Aid and Walgreens certify substantial compliance with second request)
- MXL +4% (to join S&P SmallCap 600)
- LNTH +3.9% (to join S&P SmallCap 600)
- XXII +3.1% (announces new manufacturing agreements; raises FY17 revenue guidance)
- AAL +2.4% (reports April traffic; raises its 2Q17 TRASM)
- PLX +2.2% (FDA cleared an IND for a clinical trial evaluating the safety and efficacy of administering 2 mg/kg of pegunigalsidase alfa once monthly in Fabry patients; co expects to commence this study in 3Q17)
- VVV +2% (to join S&P MidCap 400)
- DXC +1.4% ( positive mention by Glenview Capital's Larry Robbins at Sohn)
- PNR +1.4% (approves plan to separate into two independent, publicly-traded companies; co expects to complete the separation in 2Q18)
Analyst comments:
- ALV +1% (upgraded to Buy from Hold at Jefferies)
- JD +0.8% (upgraded to Mkt Perform from Underperform at Bernstein)